• Home
  • About Us
  • Blog

Pulmonary Hypertension RN

  • What is Pulmonary Hypertension?
    • What is Pulmonary Hypertension?
    • Pulmonary Hypertension Symptoms
    • Types of Pulmonary Hypertension
    • Causes of Pulmonary Hypertension
    • PH vs. PAH
    • Diastolic Heart Failure vs. PAH
    • WHO Group 3 Pulmonary Hypertension, IPF & COPD
    • Pulmonary Veno-Occlusive Disease
    • Hereditary Hemorrhagic Telangiectasia (HHT)
      • Hereditary Hemorrhagic Telangiectasia (HHT) Treatment
    • Functional Classification of Pulmonary Hypertension
    • Congenital Heart Disease
      • Eisenmenger’s Syndrome
      • Update on Management of PAH-CHD
      • Congenital Heart Disease & Sleep Apnea
      • Complex Congenital Heart Disease
      • Atrial Septal Defect and Pulmonary Arterial Hypertension
    • Pediatric Pulmonary Arterial Hypertension
    • Sickle Cell and Pulmonary Hypertension
    • Stimulant Associated Pulmonary Arterial Hypertension
    • Porto-Pulmonary Syndrome
    • Research, Life Expectancy & Prognosis for PH
  • Diagnosing & Monitoring PAH
    • Pulmonary Arterial Hypertension Diagnosis
    • How Am I Doing? Assessing Your PAH.
    • Blood Tests
    • Cardiopulmonary Exercise Test (CPET)
    • CT (Computed Tomography) Scan
    • Echocardiogram: An Overview
    • Echocardiogram: A Detailed Look
    • Pulmonary Function Tests (PFTs)
    • Right Heart Catheterization
    • Six Minute Walk
    • Ventilation Perfusion Scan (VQ Scan)
    • CTEPH
      • CTEPH: WHO Group 4 Pulmonary Hypertension
      • PTE (Pulmonary Thromboendarterectomy) Surgery
      • Adempas used to Treat PAH and CTEPH
  • PAH Treatment
    • Pulmonary Hypertension Centers
    • Pulmonary Hypertension Treatments
    • Continuously Infused Therapies Used to Treat PH
    • Prostanoids for Treatment of PH
    • Adcirca and Revatio Used to Treat Pulmonary Arterial Hypertension (PAH)
    • Adempas used to Treat PAH and CTEPH
    • Tracleer, Letairis, and Opsumit Treatments
    • Oxygen Therapy for Pulmonary Hypertension
    • Salt and Water Restrictions
    • Exercise & PAH
    • Diuretics
    • Blood Thinners
    • Getting the Most Out of PAH Therapy
      • Letairis
      • Opsumit
      • Sildenafil (Revatio)
  • Research
  • FAQ’s
    • Implanted Remodulin Pump, Right Heart Catheterization, PAH & Pregnancy
    • Oral Treatments, Care Centers & Hole in Heart
    • FAQ’s: Altitude, Cold & Allergy Medications
    • FAQ’s: Psoriasis, Idiopathic PAH, Contraceptives & PAH
    • FAQ’s: Causes of Pulmonary Hypertension, Symptom Frequency & Care Centers
    • FAQ: PAH Experts, Pregnancy, Mild PAH & Vacationing
    • FAQ’s: CTEPH, Blood Clots, Corrective Surgery & PAH Care Centers
    • FAQ’s: VQ Scans & PAH Curable?
    • FAQ’s: Mild Pulmonary Hypertension?
    • FAQ’s: Boating, Swimming & Eating with PAH
    • FAQ’s: Borderline Pulmonary Hypertension, Hand Swelling, Children with PAH, Costs

Financial Assistance for Pulmonary Hypertension Patients with Medicare, Medicaid & Military Benefits

February 8, 2018 By Dr. Jeremy Feldman

 financial assistance for PAH patients

Assistance Now Available.

Where to get financial assistance for the very expensive drugs used to treat Pulmonary Arterial Hypertension remains a hot topic. With an average treatment cost of around $100,000 per PAH patient per year, financial assistance is in great demand.

Pulmonary Hypertension patients that are uninsured or privately insured have options for financial assistance. Click here to learn more about foundations currently offering assistance. However, patients on government plans like Medicare, Medicaid or Military Benefits are often left out of drug manufacturer assistance programs. The Patient Advocate Foundation (PAF) is one fund that can help this population of PAH patients.

What are Patient Advocate Foundation’s Eligibility Requirements?

  • To receive any PAH treatment a patient should first have a right heart catheterization to confirm the diagnosis. While PAF does not specifically state that a right heart catheterization is required to receive funding they do require a “confirmed diagnosis of Pulmonary Hypertension”.
  • The fund is open to patients within the United States insured by Medicare, Medicaid or Military Benefits.
  • The medication must be covered by the patient’s insurance and a prior authorization must be obtained. Your PAH specialist’s office will obtain the required prior authorization.
  • Patient’s income must be below 400% of the Federal Poverty Guideline (FPG). For 2018 for an individual living in one of the 48 contiguous states the income must be less than $48,560 per year. The income limit goes up for each additional family member and Alaska and Hawaii have slightly different requirements. The cost of living in your area is also considered. You can learn more about the Federal Poverty Guideline here https://aspe.hhs.gov/poverty-guidelines.

How Can PAH Patients Apply for Patient Advocate Foundation Assistance?

Patients that meet the above criteria can apply online at www.copays.org or by calling 1-866-512-3861.

What Amount of Financial Assistance Can Pulmonary Hypertension Patients Receive?

The maximum amount of assistance per year for 2018 is $9,000.

PAH patients that do not meet the criteria for this assistance program and are struggling to afford their medications should reach out to their PAH specialists. These specialty clinics will have the most up to date information on available programs and research protocols that patients may qualify for. Never discontinue treatment without speaking with your provider as this may cause serious side effects.

Filed Under: Pulmonary Hypertension Treatments

PAH Life Expectancy

PAH Research

Research, Life Expectancy & Prognosis for PH

Major Developments in Pulmonary Hypertension Affecting Prognosis 1.     Approval of

Where to Get Treatment?

CCCs for PAH

Pulmonary Hypertension Centers

Where to get treatment for pulmonary hypertension? Pulmonary arterial hypertension is a

Popular Posts

pulmonary hypertension medications

How Will I Afford My PAH Medications?

By Dr. Jeremy Feldman

The cost of Pulmonary Arterial Hypertension medications is staggering.  The least expensive medication  (generic

PAH research

Tyrosine Kinase Inhibition and Pulmonary Arterial Hypertension

By Dr. Jeremy Feldman

30 years ago PAH scientists and doctors believed that PAH was caused by inappropriate or excessive squeezing

good news in pah

 

Disclaimer

Recent Blog Posts

  • In Memoriam:  Greg Ahearn, MD June 16, 2024
  • Sotatercept (Winrevair) Approved! June 1, 2024
  • Disappointing News for Rodatristat Ethyl October 11, 2023

Categories

Archives